Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin

Nishikawa, Kazuhiro; Yamada, Yasuhide; Ishido, Kenji; Gotoh, Masahiro; Bando, Hideaki; Sugimoto, Naotoshi; Nishina, Tomohiro; Amagai, Kenji; Chìn, Keisho; Niwa, Yasumasa; Tsuji, Akihito; Imamura, Hiroshi; Tsuda, Masahiro; Yasui, Hirofumi; Fujii, Hirofumi; Yamaguchi, Kensei; Yasui, Hisateru; Hironaka, Shuichi; Shimada, Ken; Miwa, Hiroto; Hamada, Chikuma; Hyodo, Ichinosuke

doi:10.1007/s10120-016-0666-5

Cited by 3 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…nausea, vomiting and renal toxicity), but was associated with a significantly higher rate of peripheral polyneuropathy (22). In a recent phase III study comparing S-1/oxaliplatin (SOX regimen) and Cis/S-1 in Japanese OAC patients, similar results were obtained with respect to the safety issues, whereas no significant difference in terms of progression-free survival (PFS) and OS were observed between the two regimens (24,25). Haematological toxicity is reversible, nausea and vomiting are preventable, whereas renal toxicity can be monitored.…”

Section: Discussionmentioning

confidence: 75%

Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature

et al. 2017

View full text Add to dashboard Cite

Abstract. Perioperative platinum/fluoropyrimidine-based chemotherapy is the therapeutic standard for oesophagogastric cancer (OAC) patients with locoregional disease. The preoperative condition directly affects postoperative prognosis; thus, particularly for elderly patients, a perioperative regimen with a favourable side effect profile is highly desirable. In the palliative setting, the combination of cisplatin and S-1 (Cis/S-1) was found to be as effective as cisplatin/5-fluorouracil, but with a more favourable side effect profile. However, no data on this combination have been reported in the perioperative setting in Caucasian patients. To the best of our knowledge, this is the first report on the treatment outcome of two elderly Caucasian OAC patients with locoregional disease receiving two neoadjuvant 4-week cycles of intravenous Cis/S-1. Both patients tolerated the doublet therapy well. No treatment delay or dose reduction was required. In both cases, preoperative staging revealed a clear response and complete surgical resection could be performed without any complications.

show abstract

Section: Discussionmentioning

confidence: 75%

Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Therefore, debate continues about the clinical significance of the anatomic sites of new lesions. However, in view of previous reports that the number of metastatic sites is a prognostic factor [ 33 ] and that progression accompanied by new lesions has a strong negative impact on the prognosis of AGC [ 27 ], not including new lesions in the sum of tumor diameters may lead to underestimation of tumor burden. New lesions especially in an organ different from that involved before initiation of nivolumab could be included in the calculation of TGR and HPD in patients with AGC.…”

Section: Discussionmentioning

confidence: 99%

“…However, peritoneal metastasis is not included in the original definition of HPD because it is not a measurable lesion. Moreover, there has also been a report suggesting that disease progression accompanied by new lesions has a strong negative impact on the prognosis in patients with AGC [ 27 ]. Given the lack of difference in the biological mechanism of ICI-induced rapid progression between measurable lesions and non-measurable/new lesions, exclusion of peritoneal metastasis and new lesions from the definition of HPD may lead to underestimation of accelerated tumor growth during treatment with ICI in patients with AGC.…”

Section: Introductionmentioning

confidence: 99%

Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background Accelerated tumor growth during immunotherapy in pre-existing measurable lesions, hyperprogressive disease (HPD), has been reported. However, progression of non-measurable lesions and new lesions are frequently observed in patients with advanced gastric cancer (AGC). Methods This retrospective study involved AGC patients at 24 Japanese institutions who had measurable lesions and received nivolumab after ≥ 2 lines of chemotherapy. HPD was defined as a ≥ two-fold increase in the tumor growth rate of measurable lesions. The pattern of disease progression was classified according to new lesions in different organs and ascites appeared/increase of ascites. Results Of 245 patients, 147 (60.0%) showed progressive disease (PD) as the best response and 41 (16.7%) showed HPD during nivolumab monotherapy. There was no significant difference in overall survival (OS) between patients with HPD and those with PD other than HPD (median OS 5.0 vs 4.8 months; hazard ratio [HR] 1.0, 95% confidence interval [CI] 0.6–1.5; p = 1.0). Fifty-three patients developed new lesions in different organs and 58 had appearance/increase of ascites; these patients showed shorter OS than those without each of these features (median OS 3.3 vs 7.1 months, HR 1.8, 95% CI 1.2–2.7, p = 0.0031 for new lesions, and 3.0 vs 7.8 months, HR 2.6, 95% CI 1.8–3.8, p < 0.0001 for ascites). Thirty-one patients who had both features showed the worst prognosis (median OS 2.6 months). Conclusions New lesions in different organs and appearance/increase of ascites, rather than the original definition of HPD, are the patterns of disease progression associated with poor prognosis in AGC patients receiving nivolumab whose best response was PD.

show abstract

“…According to the Japanese guidelines for gastric cancer, S-1 plus cisplatin is the recommended systemic treatment as first-line chemotherapy for patients with HER2-negative disease (2,15,16). S-1 plus oxaliplatin is also recommended chemotherapy regimen for unresectable advanced gastric cancer and was proven to be effective in pivotal trials (17)(18)(19)(20). Recent developments in second-line and further treatments, such as ramucirumab, nivolumab, and trifluridine/tipiracil, for metastatic gastric cancer have improved overall survival and quality of life (21)(22)(23).…”

Section: Discussionmentioning

confidence: 99%

Successful Conversion Surgery for Advanced Gastric Cancer With Multiple Liver Metastases Following Ramucirumab Plus Paclitaxel Combination Treatment

Namikawa

Marui

Yokota

et al. 2021

In Vivo

View full text Add to dashboard Cite

Aim: To present the case of a patient with unresectable gastric cancer showing a remarkable effect by second-line drug treatment with ramucirumab plus paclitaxel and conversion surgery. Case Report: A 68-year-old woman who was diagnosed with gastric cancer was referred to us. Esophagogastroduodenoscopy showed an ulcerated lesion with an irregular nodulated border in the lower third of the stomach, and histology of biopsied specimens indicated a poorly differentiated adenocarcinoma. Enhanced computed tomography revealed extensive invasion of the liver, and the patients was treated using S-1 plus oxaliplatin as first-line chemotherapy. Because she developed liver metastases, the treatment regimen was changed to ramucirumab plus paclitaxel as the second-line treatment. After four cycles of weekly paclitaxel with ramucirumab treatment, the liver metastases had completely disappeared. Because no other metastatic lesions in other organs were detected, we performed total gastrectomy with D2 lymphadenectomy. The macroscopic findings of the surgically resected specimen revealed an ulcerated lesion with an irregularly modulated lesion measuring 9.5×4.5 cm. Pathological analysis demonstrated a poorly differentiated adenocarcinoma in the stomach, with invasion to the liver through the serosal layer, and seven lymph node metastases. The postoperative course was unremarkable, and she received ramucirumab in combination with paclitaxel treatment. However, liver metastasis appeared at 4 months after the operation, for which she was treated with irinotecan. Although the patient continued to receive irinotecan chemotherapy for 10 months, her general condition gradually deteriorated, and she was started on best supportive care 13 months after conversion surgery. Conclusion: Conversion surgery may prolong survival not only through first-line but also second-line treatments in selected patients with unresectable advanced gastric cancer; however, assessments of additional cases and further studies are required to establish this treatment strategy.

show abstract

Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin

Cited by 3 publications

References 12 publications

Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature

Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature

Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan

Successful Conversion Surgery for Advanced Gastric Cancer With Multiple Liver Metastases Following Ramucirumab Plus Paclitaxel Combination Treatment

Contact Info

Product

Resources

About